Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | Updates on the use of zanubrutinib in WM patients intolerant to ibrutinib or acalabrutinib

Mazyar Shadman • 29 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Acalabrutinib BTK inhibitors Ibrutinib Zanubrutinib

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, briefly discusses the safety and efficacy of zanubrutinib in patients with Waldenström’s macroglobulinemia (WM) who are intolerant to ibrutinib or acalabrutinib. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mazyar Shadman

1:17
Dose reductions to manage AEs of ibrutinib treatment for CLL
Mazyar Shadman • 10 Dec 2023
1:32
CD20-targeted CAR T-Cell therapy for patients with indolent B-cell NHL
Mazyar Shadman • 10 Dec 2023
1:06
Zanubrutinib in patients with B-cell malignancies who are acalabrutinib-intolerant
Mazyar Shadman • 10 Dec 2023
3:09
Retrospective analysis of clinical outcomes in pts with LBCL receiving CAR-T or autoSCT while in CR
Mazyar Shadman • 10 Dec 2023

Related Videos

0:46
The urgency of diagnosing and treating patients with Castleman disease
Karthik Ramasamy • 28 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals